Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 247

1.

Clinical manifestation of hemophilia A in the absence of mutations in the F8 gene that encodes FVIII: role of microRNAs.

Jankowska KI, McGill J, Pezeshkpoor B, Oldenburg J, Atreya CD, Sauna ZE.

Transfusion. 2019 Nov 29. doi: 10.1111/trf.15605. [Epub ahead of print]

PMID:
31785023
2.

The Plasma Factor XIII Heterotetrameric Complex Structure: Unexpected Unequal Pairing within a Symmetric Complex.

Singh S, Nazabal A, Kaniyappan S, Pellequer JL, Wolberg AS, Imhof D, Oldenburg J, Biswas A.

Biomolecules. 2019 Nov 21;9(12). pii: E765. doi: 10.3390/biom9120765.

3.

A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.

Young G, Liesner R, Chang T, Sidonio R, Oldenburg J, Jiménez-Yuste V, Mahlangu J, Kruse-Jarres R, Wang M, Uguen M, Doral MY, Wright LY, Schmitt C, Levy GG, Shima M, Mancuso ME.

Blood. 2019 Dec 12;134(24):2127-2138. doi: 10.1182/blood.2019001869.

4.

Treatment of the antiphospholipid syndrome with direct oral anticoagulantsPosition statement of German societies.

Bauersachs R, Langer F, Kalka C, Konstantinides S, Klamroth R, Oldenburg J, Schellong S, Scholz U, Stücker M, Lindhoff-Last E.

Vasa. 2019 Nov;48(6):483-486. doi: 10.1024/0301-1526/a000815. Epub 2019 Aug 20.

5.

Characterization of the mutation spectrum in a Pakistani cohort of type 3 von Willebrand disease.

Ahmed S, Yadegari H, Naz A, Biswas A, Budde U, Saqlain N, Amanat S, Tariq S, Raziq F, Masood S, Pavlova A, Shamsi TS, Oldenburg J.

Haemophilia. 2019 Nov;25(6):1035-1044. doi: 10.1111/hae.13841. Epub 2019 Sep 18.

PMID:
31532876
6.

Assessing bleeding rates, related clinical impact and factor utilization in German hemophilia B patients treated with extended half-life rIX-FP compared to prior drug therapy.

Oldenburg J, Yan S, Maro G, Krishnarajah G, Tiede A.

Curr Med Res Opin. 2020 Jan;36(1):9-15. doi: 10.1080/03007995.2019.1662675. Epub 2019 Sep 13.

PMID:
31469321
7.

Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results.

Shapiro AD, Angchaisuksiri P, Astermark J, Benson G, Castaman G, Chowdary P, Eichler H, Jiménez-Yuste V, Kavakli K, Matsushita T, Poulsen LH, Wheeler AP, Young G, Zupancic-Salek S, Oldenburg J.

Blood. 2019 Nov 28;134(22):1973-1982. doi: 10.1182/blood.2019001542.

8.

Structure functional insights into calcium binding during the activation of coagulation factor XIII A.

Singh S, Dodt J, Volkers P, Hethershaw E, Philippou H, Ivaskevicius V, Imhof D, Oldenburg J, Biswas A.

Sci Rep. 2019 Aug 5;9(1):11324. doi: 10.1038/s41598-019-47815-z.

9.

Increased Activated Protein C Response Rates Reduce the Thrombotic Risk of Factor V Leiden Carriers But Not of Prothrombin 20210G>A Carriers.

Rühl H, Berens C, Winterhagen FI, Reda S, Müller J, Oldenburg J, Pötzsch B.

Circ Res. 2019 Aug 16;125(5):523-534. doi: 10.1161/CIRCRESAHA.119.315037. Epub 2019 Jul 17.

PMID:
31314700
10.

Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review.

Yu JK, Iorio A, Edginton AN; WAPPS co‐investigators.

Res Pract Thromb Haemost. 2019 May 20;3(3):528-541. doi: 10.1002/rth2.12204. eCollection 2019 Jul. Review. Erratum in: Res Pract Thromb Haemost. 2019 Sep 16;3(4):771.

11.

Efficacy and safety of simoctocog alfa (Nuwiq®) in patients with severe hemophilia A: a review of clinical trial data from the GENA program.

Lissitchkov T, Klukowska A, Pasi J, Kessler CM, Klamroth R, Liesner RJ, Belyanskaya L, Walter O, Knaub S, Bichler J, Jansen M, Oldenburg J.

Ther Adv Hematol. 2019 Jun 26;10:2040620719858471. doi: 10.1177/2040620719858471. eCollection 2019. Review.

12.

Activity Pattern Analysis Indicates Increased but Balanced Systemic Coagulation Activity in Response to Surgical Trauma.

Friedrich MJ, Schmolders J, Rommelspacher Y, Strauss A, Rühl H, Mayer G, Oldenburg J, Wirtz DC, Müller J, Pötzsch B.

TH Open. 2018 Oct 1;2(4):e350-e356. doi: 10.1055/s-0038-1673390. eCollection 2018 Oct.

13.

Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A.

Müller J, Pekrul I, Pötzsch B, Berning B, Oldenburg J, Spannagl M.

Thromb Haemost. 2019 Sep;119(9):1384-1393. doi: 10.1055/s-0039-1692427. Epub 2019 Jun 16.

14.

Risk stratification integrating genetic data for factor VIII inhibitor development in patients with severe hemophilia A.

Bachelet D, Albert T, Mbogning C, Hässler S, Zhang Y, Schultze-Strasser S, Repessé Y, Rayes J, Pavlova A, Pezeshkpoor B, Liphardt K, Davidson JE, Hincelin-Méry A, Dönnes P, Lacroix-Desmazes S, Königs C, Oldenburg J, Broët P; ABIRISK consortium.

PLoS One. 2019 Jun 13;14(6):e0218258. doi: 10.1371/journal.pone.0218258. eCollection 2019.

15.

F8 Inversions at Xq28 Causing Hemophilia A Are Associated With Specific Methylation Changes: Implication for Molecular Epigenetic Diagnosis.

Jamil MA, Sharma A, Nuesgen N, Pezeshkpoor B, Heimbach A, Pavlova A, Oldenburg J, El-Maarri O.

Front Genet. 2019 May 29;10:508. doi: 10.3389/fgene.2019.00508. eCollection 2019.

16.

Identification of Potential Novel Interacting Partners for Coagulation Factor XIII B (FXIII-B) Subunit, a Protein Associated with a Rare Bleeding Disorder.

Singh S, Akhter MS, Dodt J, Volkers P, Reuter A, Reinhart C, Krettler C, Oldenburg J, Biswas A.

Int J Mol Sci. 2019 May 31;20(11). pii: E2682. doi: 10.3390/ijms20112682.

17.

Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study.

Oldenburg J, Hay CRM, Jiménez-Yuste V, Peyvandi F, Schved JF, Szamosi J, Winding B, Lethagen S.

BMJ Open. 2019 May 30;9(5):e028012. doi: 10.1136/bmjopen-2018-028012.

18.

The role of variant alleles of the mannose-binding lectin in the inhibitor development in severe hemophilia A.

Ulrich-Merzenich G, Hausen A, Zeitler H, Goldmann G, Oldenburg J, Pavlova A.

Thromb Res. 2019 Jul;179:140-146. doi: 10.1016/j.thromres.2019.05.005. Epub 2019 May 9.

PMID:
31141731
19.

Estimation of Nuwiq® (simoctocog alfa) activity using one-stage and chromogenic assays-Results from an international comparative field study.

Tiefenbacher S, Albisetti M, Baker P, Kappert G, Kitchen S, Kremer Hovinga JA, Pouplard C, Scholz U, Ternisien C, Borgvall C, Vicente T, Belyanskaya L, Walter O, Oldenburg J; Nuwiq Field Study Participating Laboratories.

Haemophilia. 2019 Jul;25(4):708-717. doi: 10.1111/hae.13763. Epub 2019 May 20.

20.

Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIII.

Kearney S, Raffini LJ, Pham TP, Lee XY, von Mackensen S, Landorph A, Takedani H, Oldenburg J.

Patient Prefer Adherence. 2019 Apr 9;13:497-513. doi: 10.2147/PPA.S196103. eCollection 2019.

Supplemental Content

Loading ...
Support Center